Irloxacin
Based on 1 Customer Validation
Irloxacin (Pirfloxacin) is a quinolone antibacterial agent. Irloxacin shows greater activity with an acid pH. Irloxacin has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria. Orally active.
For research use only. We do not sell to patients.
- Purity : 98.02%
- CAS No.: 91524-15-1
- Formula: C16H13FN2O3
- Molecular Weight:300.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Chemical Information
-
CAS No. 91524-15-1
-
Appearance Solid
-
Molecular Weight 300.28
-
Formula C16H13FN2O3
-
Color White to off-white
-
SMILES
CCN1C2=CC(N3C=CC=C3)=C(F)C=C2C(C(C(O)=O)=C1)=O
-
Synonyms
Pirfloxacin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 33.33 mg/mL (111.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Casal M, et al. Preliminary study of the in vitro activity of irloxacin against mycobacteria. Chemotherapy. 1995;41(3):204-207. [Content Brief]
[2]. Guzmán A, et al. Acute and subchronic toxicity studies of the new quinolone antibacterial agent irloxacin in rodents. Arzneimittelforschung. 1999;49(5):448-456. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3302 mL | 16.6511 mL | 33.3023 mL | 83.2556 mL |
| 5 mM | 0.6660 mL | 3.3302 mL | 6.6605 mL | 16.6511 mL | |
| 10 mM | 0.3330 mL | 1.6651 mL | 3.3302 mL | 8.3256 mL | |
| 15 mM | 0.2220 mL | 1.1101 mL | 2.2202 mL | 5.5504 mL | |
| 20 mM | 0.1665 mL | 0.8326 mL | 1.6651 mL | 4.1628 mL | |
| 25 mM | 0.1332 mL | 0.6660 mL | 1.3321 mL | 3.3302 mL | |
| 30 mM | 0.1110 mL | 0.5550 mL | 1.1101 mL | 2.7752 mL | |
| 40 mM | 0.0833 mL | 0.4163 mL | 0.8326 mL | 2.0814 mL | |
| 50 mM | 0.0666 mL | 0.3330 mL | 0.6660 mL | 1.6651 mL | |
| 60 mM | 0.0555 mL | 0.2775 mL | 0.5550 mL | 1.3876 mL | |
| 80 mM | 0.0416 mL | 0.2081 mL | 0.4163 mL | 1.0407 mL | |
| 100 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8326 mL |